The human multidrug resistance P-glycoprotein is a member of the ABC superfamily of membrane transporters. Over 50 members of this superfamily have now been identified, in species including bacteria, yeasts, plants, insects and mammals. These transporters are associated with a wide variety of biological processes and, in man, several are associated with clinical disorders. An overview of the structure and function of ABC transporters will be presented.
Drug resistance constitutes a major problem in the treatment of human malignancies. Evidence is accumulating that multidrug resistance is one form of drug resistance that has a role in human tumors. The multidrug resistance phenotype is associated with the overproduction of P-glycoprotein, an integral membrane phosphoprotein that acts as an energydependent drug efflux pump with a broad specificity for hydrophobic antitumor drugs. Each half of P-glycoprotein is designated as a cassette that contains six putative transmembrane domains. Each cassette is followed by a nucleotide binding domain and the two cassettes are joined by a linker region. The use of '25I-iodoarylazidoprazosin and 3H-azidopine, two photoaffinity probes that bind specifically to p-glycoprotein, and immunological mapping methods have located major photolabelled drug binding domains in each cassette, immediately C-terminal to TM6 and TM12.
A combination of cyanogen bromide digestion and immunoblot analysis has been usd to domain map the phosphorylation sites in p-glycoprotein. The majority of phosphorylation occurs within a single cyanogen bromide fragment (amino acids 627-682) that encompasses the majority of the linker region. Our studies indicate that in vitro protein kinase C and protein kinase A phosphorylation occurs at serines 669 and 681, respectively. The effects of phosphorylation on p-glycoprotein function are being evaluated. Multidrug resistance refers to the type of resistance to cytostatic drugs with different chemical structures and different cellular targets caused by mechanisms that result in a decreased concentration of drugs at the target sites. ATP dependent drug transporters have been identified recently in mammalian cells, including human cancer cells. Upregulation of such drug transporter activity frequently occurs upon in vitro selection of tumor cell lines with cytostatic drugs.
I will discuss data from our laboratory on daunorubicin (DNR) transport by three drug transporters: P-glycoprotein (Pgp), 'GLC4/ADR' type (small cell lung cancer) and 'SW- 1573/2R120' type (non-small cell lung cancer). Evidence for active drug transport in these systems is: (a) DNR efflux is ATP-dependent; (b) DNR efflux is against a concentration gradient; (c) upon permeabilization of the plasma membrane with low digitonin concentrations there is DNR net influx, showing that the cytoplasmic drug concentration is kept below the extracellular concentration. Furthermore, differences in passive drug permeation (passive permeation coefficient), intracellular pH or DNA content could not explain the DNR accumulation defects.
Additional evidence for presence of a drug transporter is the saturability of the active DNR transport; assuming simple Michaelis-Menten kinetics and no preference for neutral DNR transport by the pump we could calculate an apparent Km of 1.5 tLM for DNR transport by Pgp as well as the 'GLC4/ADR' transporter.
A further characteristic of drug transporters is the possibility to inhibit DNR transport by agents that compete for the drug interaction with the transporter. An example will be shown of the competitive interaction of the isoflavonoid genistein with the 'GLC4/ADR' transporter.
Another characteristic of many MDR cells is the relatively more decreased accumulation of anthracyclines in the nucleus (N), compared to the cytoplasm (C), leading to e.g. a lower doxorubicin fluorescence N/C ratio in MDR compared to sensitive cells. A decrease in drug accumulation plus altered drug distribution in many cases may explain the resistance in (Pgp)/MDR cells. Also this method can be used to screen for an MDR phenotype in individual cells, e.g. in human acute myeloid leukemic blasts, using fluorescence microscopy.
We conclude that future efforts to identify functional drug (1992) . J. Clin. Oncol., 10, 1624 -1634 . Lum, B.L. & others (1992 . J. Clin. Oncol., 10, 1635 -1642 . Sikic, B.I. (1993 . J. Clin. Oncol., 11, 1629 Oncol., 11, -1635 The Gordon Hamilton-Fairley Memorial Lecture Kawai et al., 1990, J. Biol. Chem., 265, 13137) . Recently it has been proposed that at least some component of CDDP accumulation occurs through a gated ion channel (Gately & Howell, 1993 , Br. J. Cancer, 67, 1171 .
CDDP resistance due to reduced drug accumulation may also be circumvented by novel Pt-based complexes. Studies using the more lipophilic Pt drug JM216 [bis-acetatoammine-dichloro-cyclohexylamine platinum (IV)] (currently in phase I clinical trial as the first orally administrable Pt drug) have shown circumvention of CDDP-resistance in accumulation defective human ovarian carcinoma 41McisR cells (Kelland et al., 1992, Cancer Res., 52, 3857 [Bosanquet, A.G. (1991, Lancet, 337, 711] . Fresh isolated human tumour cells were incubated with 1.5-380,ug/ml 8-Cl-cAMP for the 4 days of the assay to identify an LC9,. Two of the three acute myeloid leukaemia (AML) specimens were sensitive in vitro (LC90s = 1.5, 12 ytg/ml) compared with the median of all specimens tested of 38 Ag/ml. This confirms observations that AML cell lines are sensitive to this drug [Cho-Chung] . Non-Hodgkin's lymphoma and chronic lymphocytic leukaemia specimens showed less sensitivity with LCgos of 24->380jig/ml. Two specimens that contained only normal cells at the end of the incubation period were very resistant to the drug (LC90s>> 380 jig/ml) suggesting a good in vitro therapeutic index. We correlated these results with the LCgos of the similar drugs fludarabine (2-fluoro-ara-AMP, Fl) and cladribine (2-Cldeoxyadenosine, CDA). Whilst Fl and CDA were strongly cross resistant (n = 30, r2= 0.72, P = 5 x 10-9) there was little cross resistance of these drugs to 8-Cl-cAMP (8-ClcAMP vs. Fl, n = 30, r2 = 0.07, P = 0.16; 8-Cl-cAMP vs. CDA, n = 31, r2= 0.19, P =0.015). These results suggest a role for 8-Cl-cAMP in leukaemias and lymphoma and especially against AML. Brefeldin A, a fatty acid derivative of fungal origin, inhibits movement of membrane proteins from the endoplasmic reticulum to the Golgi and hence causes disassembly of the Golgi apparatus (Lippincott-Schwartz et al., Cell, 60, 821, 1990 1009, 1991) . We have shown that these cells are also resistant to the cytotoxic effects of Brefeldin A such that no cell kill was observed at the limit of solubility of Brefeldin A (100 jLg/ ml, 357 liM).
It has been suggested that accumulation of cytotoxic drugs in intracellular compartments and increased vesicular trafficking may play a role in drug resistance. Treatment of multidrug-resistant breast (MCF7Adr) and ovarian (2780AD) cell lines with brefeldin A at concentrations shown to disrupt the Golgi apparatus had no effect on sensitivity to doxorubicin. This suggests that this is not an important mechanism in these cell lines even though we were able to demonstrate co-localisation of doxorubicin and BODIPY ceramide in the breast cell line.
These results suggest that brefeldin A has potent antitumour activity and that the mechanism of action may be related to effects on intracellular membrane trafficking. It has been suggested that the essential fatty acids (EFAs) of the n-6 series promote the growth of tumour cells while the EFAs of the n-3 series inhibit the growth of these cells. However there is some controversy as to whether all members of the n-6 series promote the growth of tumour cells. The aim of this study was to determine the effects of two EFAs, linoleic (Cl8:2 n-6; LA) and y-linolenic (C18:3 n-6; GLA) acids, on the growth of human colonic carcinoma cells (HT115) in culture. Cells were grown in monolayer culture under standard conditions in medium supplemented with 10% (v/v) horse serum. Cells were exposed to the EFAs for 96 h and cell growth analysed by changes in cell number, protein content and DNA synthesis. Polyamine content was also measured as an index of the rate of cell growth. LA increased both protein content and cell number at concentrations of 5 and 20 g/ml with little effect on the cell viability. In contrast, GLA at the same concentrations had little effect on protein content by inhibited cell division, as measured by change in cell number, and viability (Table 1) . '31I-meta-iodobenzylguanidine (mIBG) is concentrated in sympathetic neurones, adrenal medullary cells and neural crestderived tumours by an active process which is mediated by the noradrenaline transporter. Targeted radiotherapy ofneuroblastoma using '3I-mIBG currently provides one of the best examples of selective anti-cancer therapy using radionuclides.
In order to identify those patients for whom 3'I-mIBG therapy will be appropriate, and to estimate dosimetry and response to this form of treatment, a pre-therapy "31I-mIBG tracer study is usually carried out. This procedure, however, is only useful in patients with residual macroscopic tumour.
In the pursuance of a cost-effective alternative to timeconsuming mIBG scintigraphic procedures ofdubious precision and of a procedure which should be applicable to all patients irrespective of disease status, we evaluated the potential of reverse transcription followed by the polymerase chain reaction (RT-PCR) to predict mIBG uptake. The expression of the noradrenaline transporter gene was compared with that of the 28S rRNA gene in six human neuroblastoma cell lines and in three non-neural crest-derived cell lines. Transcription of the noradrenaline transporter gene was observed in five out of six neuroblastoma cell lines but in none of the control cells.
The RT-PCR procedure was specific (target mRNA sequences were absent in control cells, and the PCR product and its restriction endonuclease-derived fragments were of the predicted sizes), reproducible (coefficient of variation >13.2%) and sensitive (detection limit <50 ng of total RNA). A highly significant correlation was established (P < 0.01) between gene expression and active cellular accumulation of mIGB. It is suggested that semi-quantitative evaluation of noradrenaline transporter gene transcripts may be predictive of mIBG uptake by tumours in vivo. Mutations and over-expression of the p53 gene have been reported to be one of the most common genetic alterations in human malignancy. The determination of such abnormalities is usually by immunoprecipitation, sequencing or by immunocytochemistry. In the present study we have examined tumour cells from frozen bladder tumours of 14 patients using flow cytometry. The panel of FITC conjugated antibodies used included four to different p53 epitopes, and one to c-erbB2. We employed a permeabilisation process to the cells using saponin which allowed the simultaneous assessment of surface and intercellular components. Titration of the conjugated antibodies was performed to determine their optimum concentrations.
The presence of aneuploidy was highly associated with p53-240 (P = 0.007), p53-DO7 (P = 0.035) and c-erbB-2 (P = 0.0023) but not with expression of p53-CM1 or p53-1801. Similar results were seen in 12 tumour lines tested where the tumours could be separated into different groups based upon their p53 epitope expression. High correlations were also found between the presence of c-erbB2 and both p53-DO7 (P = 0. These results indicate that two regions, with allelic imbalance at 3p24 and 17pl2-p l 1.1 have been found in SCCHN and these may represent sites with novel tumour suppressor genes. tumour types. The ERBB2 oncogene which is on chromosome 1 7q, is frequently amplified in breast cancer. We have shown by Southern blot analysis that in three out of six tumours with ERBB2 amplification that the amplicon can encompass ERBB2, RARa and topoIIa. Interestingly, although these three genes are co-amplified the levels of amplification of each locus within each tumour can vary. In tumour 2, all three genes are amplified to a similar extent, whereas tumours 1 and 3 display higher levels of topoIIa and RARoa amplification respectively. These data suggest amplicon evolution to be a complex process. , 148, 441-445, 1992) . mRNA levels of the MDR1 gene (which encodes P-glycoprotein) were determined by a quantitative PCR-based transcript assay and Northern blot hybridisation. While the sensitive parental line, KK47, had low levels similar to those seen in primary superficial bladder tumors, from which it was derived, the KK47/ADM resistant line had 55-fold higher levels (P = 0.0023), more comparable with the levels found in high MDR1 expressing adrenal tissue and 10-fold higher than any bladder tumor sample we have analysed. Southern blot analysis of MDR1 gene copy numbers revealed a 5-fold increase in the gene copy number of the KK47/ADM cellline when compared to that of its parental KK47 line. Results thus show increased transcription to be the predominant mechanism of MDR1 overexpression in the KK47/ ADM cell line.
Verapamil could not completely overcome the resistance of KK47/ADM to doxorubicin (Kimiya et al.) suggesting that while overexpression of the MDR1 gene is the principal mechanism of drug resistance, other mechanisms may be present which play a smaller but none the less contributory role. Transcript levels of the MRP gene (associated with non-P-glycoprotein mediated MDR) were determined and found to be 1.7-fold higher in KK47/ADM than its parental line, though this result was not significant (P = 0.26). The N-myc oncogene is amplified in approximately 30% of neuroblastoma. It is well established that cases of neuroblastoma with amplified N-myc have markedly poorer prognosis than those in which N-myc copy number is not elevated. The mechanism for this association is not known but may be related to cellular resistance to radiation or cytotoxic drugs.
Seven human neuroblastoma cell lines were used to investigate the relationship between N-myc copy number or expression and sensitivity to ionising radiation and to cisplatin. N-myc copy number was assessed by Southern blotting and hybridisation using the p-Nbl probe. The signal produced by DNA from the cell lines was compared with that of single copy N-myc from normal human placental DNA. A range of N-myc copy numbers from 1-800 was found. Expression levels of N-myc m-RNA were compared by 'dot blotting' and subsequent hybridisation to the p-Nbl probe. Radiosensitivity was assessed by surviving fraction at 2 Gy (SF2) following 'Co gamma irradiation. Values ranged from 0.13-0.52. Sensitivity to cisplatin was indicated by comparison of iso-effective concentrations (concentration required to produce 1 log cell kill). These ranged from 7.5-13 t.M.
Cisplatin studies showed a correlation between N-myc copy number (though not expression) and resistance to this drug. If this relationship is causal it may explain why treatment fails in those patients with elevated N-myc copy number. However, no correlation was found between N-myc copy number or expression and sensitivity to radiation. It is possible that N-myc amplification confers resistance to some but not all treatments used in the therapy of neuroblastoma. Further investigations along these lines may lead to the investigation of agents which are most appropriate for the treatment of neuroblastoma with amplified N-myc gene. Science, 258, 484, 1992) . As CsA and FK506 are natural products possessing potent immunosuppressive properties and also the ability to act as modifiers of classical multidrug resistance (MDR), we decided to examine the activity of DSG in MDR cells. DSG contains the polyamine spermidine within its structure and can therefore be considered a spermidine analogue. Bovine serum (BS) amine oxidase catalyses the oxidative deamination of spermidine to produce aminoaldehyde, ammonia and H202. It is thought that these aminoaldehydes are responsible for the toxicity of polyamines in vitro in the presence of BS (Kunimoto et al., J. Antibiot., 38, 899, 1985) . For this reason all experiments involving incubation of cells in medium were performed in duplicate using both BS and horse serum (HS), which is low in amine oxidase content. We used the mouse tumour cell line EMT6/ P and the human small cell lung cancer line H69/P together with their P-glycoprotein (Pgp) hyperexpressing sublines EMT6/AR1.0 and H69/LX4. Cytotoxic effects were determined using the MTT COR-L23/R is a human MDR cell line which does not overexpress the MDR-1 gene or its product, P-glycoprotein (Pgp), but has high levels of the alternative transporter molecule, MRP (Cole et al. Science, 258, 1650 , 1992 . Following acute exposure to doxorubicin (DOX), the total cellular drug accumulation and intracellular drug distribution are strikingly different in COR-L23/R compared with the parental line COR-L23/P. It is known that cellular accumulation of DOX is pH and temperature dependent and that extracellular pH in tumours is frequently 0.5 pH units lower than in normal tissues. We have therefore compared the effects of changing temperature and/or extracellular pH on the anthracycline distribution in COR-L23/P and COR-L23/ R cells. Cells grown on glass coverslips were treated with DOX (20 jLM, 1 h), rinsed in ice-cold PBS, inverted onto a slide and visualised using the Biorad MRC-600 laser-assisted confocal fluorescence microscope. In COR-L23/P at 37°C and pH 7.4, fluorescence was predominantly nuclear with only sparse, punctate cytoplasmic fluorescence. By contrast, fluorescence in COR-L23/R was mainly confined to groups of perinuclear cytoplasmic vesicles with little nuclear fluorescence. In COR-L23/P, changing pH at 37°C from 5.8 to 8.6 resulted in increased nuclear fluorescence without major changes in distribution. Marked alterations were however observed in distribution with changing extracellular pH in the resistant line. At 37C and pH 5.8, fluorescence was weak and wholly restricted to the cytoplasm, whereas at pH 8.6 it was stronger, mainly nuclear and only weak cytoplasmic fluorescence was observed. At a temperature of 22C and pH 8.6 the fluorescence distribution in COR-L23/R became identical to that in COR-L23/P. This result could not be achieved by low temperature alone. A reduction in temperature to 4'C (at pH 7.4) resulted in low fluorescence, confined to the cytoplasm, in both the resistant and parental cells. It appears therefore that drug accumulation and distribution in COR-L23/R cells are dependent upon metabolic rate and upon extracellular pH, possibly due to pH-dependent changes in DOX ionisation.
The activity of deoxyspergualin in multidrug resistant
A number of chemical agents have been suggested as modifiers of non-Pgp MDR and an agent of current interest is the tyrosine kinase inhibitor genistein, which has been found to alter intracellular DOX distribution (Takeda et al., Proc. AACR, 33, 476, 1992) , and daunorubicin (DNR) accumulation (Versanvoort et al., Br. J. Cancer, Dec, 1993) in other non-Pgp MDR cell lines but not classic MDR cell lines. In COR-L23/R a non-toxic dose of genistein (400 pM, 1 h) completely restored DNR accumulation to control levels, whilst having no effect on the parental line. Confocal studies observing the effects of genistein on the intracellular DNR distribution in COR-L23/R confirmed the increased levels of drug and also patterns of intracellular distribution similar to those in parental cells. The multidrug resistance (MDR) phenotype has been shown to effect the uptake and accumulation of anthracyclines and etoposide, the drugs used in first line treatment of AML. Tested against cell lines, verapamil (Ver), cyclosporin A (CsA) and tamoxifen (Tam) have been shown to chemosensitize cells which are resistant to these drugs.
We describe a study to test the ability of these agents to modify in vitro resistance to doxorubicin (Dox), mitoxantrone (Mit) and etoposide (VP16) using fresh blast cells from 18 patients with AML, 13 on presentation and five after previous treatment. The MTT assay was used to measure cell viability after 48 h continuous drug exposure. Log dose response curves were constructed for each test and if >30% of cells survived at 1 gLg/ml for the anthracyclines and 25 jig/ml for VP16 the cells were deemed resistant. The effect of the modifier was determined by comparing the area under the curve for drug + modifier with that of drug alone. One hundred and nineteen comparisons were made overall; 41 showed an increase in sensitivity on co-incubation with a modifier. CsA (4 pM) was the most effective sensitizer showing significantly increased cytotoxicity in 24/41 (59%) comparisons (P < 0.03). Indeed, blast cells from 7/8 patients resistant to Dox were rendered sensitive with the addition of CsA. Ver (3.3 isg/ml) increased sensitivity in 12/53 (23%) cases and Tam (10 JLM) in 4/25 (16%) cases. The effect of individual modifiers was variable between patients ranging from 7/9 tests in one patient to only 1/9 tests in another. There was no difference overall in the number of cases of chemosensitization in the group of patients who had previously received treatment.
The expression of the MDR product P-glycoprotein (Pgp) was assessed using immunocytochemistry on cytospin preparations of the cell suspension used in the MTT assay and the monoclonal antibodies C219, JSB-1 and MRK16. Preliminary data suggest no correlation between Pgp expression and chemosensitization. More sensitive techniques may be required to establish Pgp expression in the cells exhibiting resistance modification.
These data suggest CsA may be the best chemosensitization agent overall in AML. They also support the clinical use of drug modification regimes identified by in vitro screening techniques for individual patients. Resistance to front line agents, such as cisplatin and its analogue carboplatin, remains a major problem in the treatment of ovarian cancer. This resistance, whether inherent or acquired, is thought to be due to increased intracellular detoxification.
We describe a study firstly, to identify resistance to these agents and secondly, to attempt to modify this resistance in vitro. One hundred and sixty-seven samples of ascitic fluid and 160 biopsy samples from 206 patients with ovarian adenocarcinoma were continuously exposed to four concentrations of cisplatin and carboplatin for 48 h. The cell viability was then assessed using the MTT assay. The success rate for the assay is currently 80%. Log dose response curves were calculated and if >30% of cells survived at 51ag/ml cisplatin or 50 tLg/ml carboplatin, the cells were deemed to be resistant. Cisplatin and carboplatin produced a similar cell kill in 76% of cases tested. The resistance rates for these agents in a group of untreated patients were 71 % for cisplatin and 54% for carboplatin; the resistance rate for carboplatin increased to 65% in a group of patients who had received previous therapy. The assay results showed a positive correlation with the clinical outcome in 18 of 25 (60%) untreated patients (P= 0.018). Sixty percent of patients treated with a drug to which their tumour was sensitive showed a complete clinical response compared with only 10% of those whose tumour was resistant.
One of the mechanisms involved in platinum resistance is thought to be increased detoxification through the glutathione (GSH) pathway. We attempted to reduce intracellular levels of GSH in vitro using buthionine sulfoxamine (BSO; 100l M) and inhibit glutathione-S-transferases (GSTs) with ethacrynic acid (ETH; 6.5 LM). Modification effect was assessed by comparing the area under the curve with that of drug alone. Forty-nine comparisons were made of the effect of these agents on cisplatin and carboplatin cytotoxicity using fresh cells from 13 patients. There was a marked variation between patients in the effect of co-incubating with BSO or ETH. BSO increased the sensitivity to carboplatin in three patients and ETH increased sensitivity to cisplatin in two patients. Indeed, in three patients, resistant cells were rendered sensitive by chemosensitization.
Variation between patients indicates the importance of in vitro screening for an effective modifier before treatment and these results support the clinical use of these resistance modifiers in the treatment of ovarian cancer. Twenty-three human tumour cell lines (lung, breast and colon) have been evaluated for their sensitivity to the quinone based anti-cancer drug E09. Sensitivity has been compared with the intra-cellular levels of DT-diaphorase and cell lines showing the lowest enzyme activity are the most resistant to E09. Dicoumarol, an inhibitor of DT-diaphorase, renders cells containing high levels of enzyme resistant to E09. Further, using pairs of Chinese hamster cells with varying levels of DT-diaphorase, resistance is observed in those cells with low levels of reductase. Taken together these results are consistent with a dominant role for two-electron reduction, catalyzed by DT-diaphorase, in the bioactivation of E09.
Factors involved in
Novel mitosenes related to E09 and mitomycin C have been synthesized. One of these (RB91008, an aziridinyl cyclopropamitosene) is 50 x more potent than E09 in V79 cells (3 h exposure in air). Treatment of cells with dicoumarol protects against the action of RB91008. Replacement of the aziridine in RB91008 with methoxy only has a slight effect on the ability of the compound to act as a substrate for DTdiaphorase but potency is reduced 1000 x. These results illustrate the importance of reductive activation for controlling toxicity but also suggest that other processes can play a crucial role in controlling cellular resistance to these quininoid compounds. Nitric oxide is an endogenous vasodilator responsible for maintaining blood vessel potency, and is generated in vivo from L-arginine by nitric oxide synthase (NOS). NOS activity may be inhibited by agents such as nitro-L-arginine (NOARG) resulting in vasoconstriction. We have recently demonstrated using 31p mrs that the transplantable murine tumour SCCVII and various spontaneous murine mammary adenocarcinomas can respond to NOARG. This was observed as a change in phosphorous metabolism indicating increased tumour hypoxia.
The induction of tumour hypoxia is sufficient to activate bioreductive drugs, in particular the agent RB 6145 developed in this Laboratory. The drug is a substituted 2-nitroimidazole which, on reductive activation by cellular reductase, is converted to a powerful DNA cross-linking agent. It is highly active in various experimental solid tumours.
Treatment in vivo of the KHT murine tumour, by combination of nitro-L-arginine and RB 6145, produced a large anti-tumour effect when measured by a post-treatment excision cell survival assay. Single doses of RB 6145, in the range 100-300 mg/kg, were followed 15 minutes later by single doses of nitro-L-arginine 5-20mg/kg. For the higher dose ranges, tumour cell-kill as measured by relative cell survival, exceeded five decades in the majority of tumours.
In vivo results including both tumour response and 31p mrs will be used to illustrate potential clinical value of this approach to overcome relatively inaccessible and chemo-resistant tumour cells. Resistance of human tumour cells to chemotherapeutic agents has been a common clinical problem. The effect of nucleoside salvage in combination with the antimetabolites 5-fluorouracil, N-(phosphonacetyl)-L-aspartate and methotrexate was investigated. A series of cell lines of common genetic origin was used which exhibit a range of differing phenotypes from normal (KMS), through immortalized (KMST) to aggressively tumourigenic (KN-NM) (Namba et al., 1987 ) (Kinsella et al., 1990 . Kinsella and Haran (1991) demonstrated that the intrinsic sensitivities of methotrexate and PALA showed increasing resistance to parallel increasing tumourigenicity with these cell lines and this was unrelated to amplification of the respective target genes. Dipyridamole, a nucleoside transport inhibitor, was used in combination with the respective drugs in standard survival assays, in normal foetal bovine serum, to assess the contribution of the salvage pathways to resistance.
The KN-NM tumourigenic cell line was totally resistant to PALA up to a concentration of 1 mM compared to an LD50 of 50 gM after the addition of dipyridamole. The KMS normal cell line had an LDs, of 5 JAM and 60 JAM respectively in the presence and absence of dipyridamole. Methotrexate gave an LDm of 2.5 JAM without dipyridamole and 0.7 JAM with dipyridamole for the KN-NM cell line. This difference has been eradicated with the KMST cell line which gave an LD50 of 0.4 JAM both with and without dipyridamole. The KN-NM cell line had an LD50 of 2.5 JAM with 5-FU both with and without dipyridamole which fell to 0.9 JAM 5-FU with and without dipyridamole for the KMS normal cell line. These data suggest that the salvage pathways are having a marked effect on resistance of the cell lines to PALA, only a moderate effect with methotrexate and no effect with 5-FU. IJC, 53, 340; 1993) . Comparing their sensitivity to heat shock, the percentage clonogenic cell survival for the bladder lines ranged from 51.6-69.3% in the bladder lines compared to only 0.8-15.6% in the testis lines following a 30min exposure to 45°C. Constitutive levels of HSP70 (72 and 73) and HSP90 showed no association with heat sensitivity, but HSP27 was virtually undetectable (Western blotting/scanning densitometry) in testis cancer cells, in contrast to the high levels detected in bladder cancer cells. Following an equitoxic heat shock, HSP72 synthesis continued for 10h in the bladder line HT1376 (45°C/60min) compared to only 4h in the testis line 833K (45°C/15min). Thermotolerance also differed between the two cell types. Following a priming heat shock at 42°C, thermotolerance developed more rapidly and was prolonged in the bladder line HT1376 compared to the testis line 833K.
In conclusion, testis tumour cells are hypersensitive to heat shock, are less able to develop thermotolerance and express HSPs, and contain low levels of HSP27. Cyclophosphamide (CP) remains widely used in the treatment of paediatric malignancy. Hepatic metabolism of CP is necessary to produce the active alkylating species phosphoramide mustard.
Several authors have demonstrated considerable interpatient variability in CP pharmacokinetics in adults with a single study linking these differences to the results of treatment. Cyclophosphamide kinetics were measured in 33 children (age 2 months-18 years). Each child received the drug as a one hour infusion (dose 0.37-2.49 g/m2). Plasma levels of CP were measured using a quantitative Thin Layer Chromatography technique. The plasma half-life (t1/2), Volume of Distribution (Vd) and Clearance (Cl) were obtained from a one compartment model with first order elimination kinetics.
Considerable inter-patient variation was seen. Cyclophosphamide t1/2 exhibited 14-fold variation with, seven-fold variation observed in Cl and four-fold variation in Vd.
Cyclophosphamide t1/2 increased with age, dose (mg/M2), and concurrent administration of allopurinol. The t1/2 in children receiving repeated courses of CP was shorter than those receiving the drug for the first time. Children who received dexamethasone prior to the study exhibited an increased Cl.
This study documents the extent of inter-patient variation amongst children with cancer. The prolonged t1/2 seen at higher doses may reflect saturation of hepatic metabolism. Other differences may be the result of inherited variation in cytochrome P450-linked enyzme activity. The influence of allopurinol and dexamethasone may be due to hepatic enzyme inhibition and induction respectively. This study suggests that concurrent medication may alter CP pharmacokinetics and thus therapeutic effect. We (and others) have recently shown that the ER is phosphorylated upon binding oestradiol. We have further shown that the human ER is phosphorylated on 4-5 sites in the presence of oestradiol and that the anti-oestrogens tamoxifen and ICI 164,384 also induce ER phosphorylation, although at much lower levels than oestradiol. Phosphoamino-acid analysis shows that most of these sites are serine residues. Using deletional analysis we have mapped the N-terminalmost phosphorylation site to serine 118. The region (region A/B), containing serine 118 is required for correct promoter and tissue-specific trans-activation by human ER and mutation of serine 118 drastically reduces trans-activation by human ER, but has no effect on DNA or hormone binding by the ER.
We have subsequently also shown that the ER can be phosphorylated in vitro by at least three protein kinases involving different signal transduction pathways.
These results and their importance for the regulation of ER function will be discussed. In the normal human breast basic fibroblast growth factor (bfgf) is concentrated in the myo-epithelial cell layer. To further define the role of bfgf in breast growth and development, we measured the ability of proteoglycans (PGs) produced by normal and malignant human breast cells to bind bfgf. Human recombinant bfgf was linked to a solid support, packed into a mini-column and the elution profiles of 35S-labelled PGs in a stepwise NaCl concentration gradient were determined. The malignant breast cell line, MCF-7 and the normal, immortalised breast cell lines, HBL-100, MCF-1OA and MTSVI-7 were all found to express bfgf-binding PGs with a similar range of affinities. The PGs derived from the culture medium contained a greater proportion of higher affinity molecules than the cell-associated PGs. To investigate normal breast cells, reduction mammoplasty tissue was digested with collagenase following which pure populations of epithelial and myo-epithelial cells were prepared from trypsin-disaggregated organoids by immunomagnetic sorting using the Epithelial Membrane Antigen (EMA) for epithelial cells and the CD10 marker for myo-epithelial cells. Cultures were also established from the collagenase digests by selecting those cells capable of adhering rapidly to a plastic substrate. These cultures, designated stromal, had a fibroblastic morphology and were negative for EMA, cytokeratins 14 and 18 and collagen IV. The stromal cultures grew extremely well while the epithelial and myo-epithelial cultures proliferated more slowly and died out after 4-5 weeks. We have demonstrated bfgf-binding PGs in stromal and epithelial cell cultures but, to date, we have been unable to do so with myo-epithelial cultures. We hope to overcome this problem by modifying the immunomagnetic sorting process and/or the culture medium. The pattern of cell adhesion molecules (CAM) i.e. leukocyte function associated antigen-3 (LFA-3) and intercellular adhesion molecule-l (ICAM-1) expression on bladder tumour biopsies and tumour cell lines was investigated using different techniques.
The results showed that 15 of the 25 tumour biopsies were negative for ICAM-1 and amongst the remaining cases, only one showed strong staining whereas, LFA-3 was expressed on 21 of 23 tumours tested. The pattern of ICAM-1 expression on tumour cell lines was very different from tumour biopsies in that there were many more strongly expressing tumours. In the case of LFA-3, whilst the results of established cell lines were very similar to those of tumour biopsies, there were no strongly expressing cases among all the seven primary lines studied, indicating that the in vitro tumour lines may not always be the true representative of the original tumour.
The comparison between ICAM-1 and class II antigen expression on tumour biopsies showed that there were 11 of 18 cases where either both these molecules were expressed together or were completely absent. In the remaining seven, there were six cases where only strong class II expression was observed.
Exposure of established cell lines to cytokines showed that interferons (IFN) a had no effect on either ICAM-1 or LFA-3 expression. Similarly, IFNy showed no effect on LFA-3 molecule. However, it induced ICAM-l on eight of 11 lines investigated, under conditions where IFNa failed to have any significant activity. The mean ± SD for control value of eight responder cell lines was 617 ± 406 and following IFNa and IFNy stimulation the values were 702 ± 563 (p = 0.022) and 943 ± 471 (p = 0.001) cpm respectively under conditions where established cell lines treated with these two cytokines showed a similar increase in the susceptibility to non-MHC-restricted cytotoxicity. Transfection of b2-m gene to correct defective class 1 antigen on a cell line had no effect on class 11 and ICAM-1 expression.
These results indicate that there is a significant minority of bladder tumours with defective CAM and this could be an important factor in the overall tumour escape mechanism(s). Binding of tumour cells to the vascular endothelium and the extracellular matrix is essential to the metastatic cascade. Blockade of this process has been shown to reduce metastases in vivo and in vitro. Integrins are known to be involved in this process. Many Integrins bind to an RGD motif which is common to many of their ligands.
The function of this motif was examined by measuring the adhesion of MCF-7 cells, a breast tumour cell line, to EAhy926, an endothelial hybridoma, using varying concentrations of two different peptides.
Confluent monolayers of EAhy926 were grown on 96-well micro-titre plates and differing concentrations of either the RGD or RGDS peptides were added. MCF-7 cells were labelled with 5'Cr and 3 x 104 cells added to the endothelial monolayer. After 2 h, non-adherent cells were removed and the remaining bound cells were lysed. The 5'Cr release was then measured using a gamma-spectrometer.
This showed that cell-cell adhesion is significantly inhibited experimentally by use of an RGD-containing peptide, but not by the tripeptide itself.
Inhibition of adhesion (%)' produced by varying concentrations of peptide Peptide 0.1 mg/ml JO Lg/ml I ig/ml 0.1 lg/ml IOng/ml I ng/ml RGD 3. Swainsonine (SW), an inhibitor of glycoprotein processing, has been shown to inhibit metastasis of murine tumours in vivo. Previously, we have observed that one mechanism of this effect is an enhancement of anti-tumour immune functions. We now show that SW also has a direct inhibitory effect on basement membrane invasion of a human colorectal cell-line, SW620, in vitro. SW620 cells were incubated with varying SW concentrations for 4 days and then plated onto basement membrane matrigel coated filters in double chamber cassettes. A 5 h membrane invasion chamber system (MICS) assay was then performed. Tumour cells invading from upper to lower chambers were stained and counted. The results are shown below as % of control tumour invasion ± s.e.
[sWJ](Ag/lml) 0 1 2 5 10 % invasion 100±3.0 48±4.9* 48±5.3* 40±3.0* 38 ± 2.6* (p <0.01 by anova compared to control, *=p <0.01 by Duncan's test).
Mechanisms of this inhibition were then investigated. SW620 tumour cells incubated with 10 jug/ml SW for 4 days were 27.5% less adherent to basement membrane matrigel after 1 h than control cells (p<0.01 by unpaired t-test). SW also increased cell-cell aggregation in SW620 tumour cell cultures:
SW620 cells pre-incubated with 10 jig/ml SW had 39% ± 6.3 of cell aggregates in the culture compared to 17.32% ± 5.1 in the controls (± = s.d., p<0.01 by Mann-Whitney U, n = 7). We then investigated the effect of SW on the expression of Ecadherin, a cell-cell adhesion molecule whose loss from cells is implicated in increased metastatic potential and incubated with fluorescein labelled anti-E-cadherin antibodies and cellexpression was increased from 18% in untreated cells to 25%±1.6 (±s.e.d. p<0 .001) in cells treated with lOtLg/ml SW. In summary, SW directly inhibits basement membrane invasion of colon tumour cells in vitro, and this effect may be related to changes in cell-matrix and cell-cell adhesion. These studies show further evidence of the potential of SW in antimetastatic therapy.
